Cargando…
Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)
RATIONALE & OBJECTIVE: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab is used in the general population to treat dyslipidemia, but little is known about the effects of alirocumab on lipid levels, biomarkers, the metabolome, and safety in individuals receiving main...
Autores principales: | East, Cara, Bass, Kyle, Mehta, Ankit, Rahimighazikalayed, Gelareh, Zurawski, Sandy, Bottiglieri, Teodoro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253651/ https://www.ncbi.nlm.nih.gov/pubmed/35801187 http://dx.doi.org/10.1016/j.xkme.2022.100483 |
Ejemplares similares
-
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019) -
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019) -
RE: Praluent (Alirocumab)-Induced Renal Injury
por: Rosenson, Robert S., et al.
Publicado: (2017) -
Mortality Benefit of Alirocumab: A Bayesian Perspective
por: Labos, Christopher, et al.
Publicado: (2019) -
Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
por: Shukla, Ajay K., et al.
Publicado: (2019)